PharmaMar Partners with Foundation for Women’s Cancer to Support D.C. National 5K Race

PharmaMar Partners with Foundation for Women’s Cancer to Support D.C. National 5K Race
0
(0)

Spain’s PharmaMar partnered with the Foundation for Women’s Cancer (FWC) on Nov. 5 to support the 8th National Race to End Women’s Cancer in Washington, D.C.

The race featured a 5k run and a one-mile walk along Pennsylvania Avenue, as well as other activities involving patients and families.

Established in 2009, the race is open to anyone wishing to participate, including physicians and healthcare professionals.

“We’re very excited and appreciative to have PharmaMar join the movement by sponsoring the 8th National Race to End Women’s Cancer,” Karen Carlson, executive director of the FWC, said in a press release. “We look forward to building upon our new partnership as we strive to increase public awareness of gynecologic cancer risk awareness, prevention, early detection and optimal treatment.”

Added Pascal Besman, chief operating officer of PharmaMar USA: “It is a wonderful opportunity for us to partner with the ‘National Race to End Women’s Cancer’ given their tremendous reach in the entire women’s cancer community of patients, caregivers, physicians, advocates and others, and given our extensive clinical trials for Zepsyre in three of these cancers. I am honored to represent PharmaMar as a proud participant in this important event.”

PharmaMar is currently awaiting data, expected in 2018, from its pivotal Phase 3 CORAIL clinical trial (NCT02421588) evaluating the efficacy and safety of Zepsyre (lurbinectedin) in platinum relapsed ovarian cancer.

Zepsyre works by inhibiting the RNA polymerase II, an enzyme essential for protein production. This kills cancer cells and stops the growth of tumors. In a Phase 2 clinical study of ovarian cancer patients who did not respond to platinum-based chemotherapy, Zepsyre induced an overall response rate of 22 percent and a disease control rate of 71 percent. Zepsyre was also found to reverse IRF-1-dependent resistance to Platinol (cisplatin) in ovarian tumors.

The company plans to start registrational trials for Zepsyre in both second-line endometrial cancer and BRCA2-mutated breast cancer next year. Zepsyre is currently awaiting approval by the U.S. Food and Drug Administration.

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • MCY-M11 Phase 1 trial
  • small inhibitor
  • lymph node removal
  • Tecentriq

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?